Fleeman N, Pilkington G, Dundar Y, Dwan K, Boland A, Dickson R et al. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technol Assess 2014; 18(40): 1-77, v-vi.
Jun M, Venkataraman V, Razavian M, Cooper B, Zoungas S, Ninomiya T et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; (10): CD008176.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). January 2013.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. December 2012.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. November 2013.
Palmer SC, Di Micco L, Razavian M, Craig JC, Perkovic V, Pellegrini F et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; (4): CD008834.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; (5): CD007784.
Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS ONE 2015; 10(7): e0132970.
Sun L, Zou L, Chen M, Liu B. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail 2015; 37(7): 1149-1156.
Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016; 67(5): 728-741.
Zhang Z, Wu P, Zhang J, Wang S, Zhang G. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83.
IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.
Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.
Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.